chrisvoncsefalvay/vaers-outcomes huggingface dataset:
occupational, physical and speech; No use to left arm, leg; right basal ganglia cerebrovascular-stroke; Wrong vaccine administered; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 67-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 25Oct2022 at 12:15 as dose 1, single (Batch/Lot number: unknown) at the age of 67 years, in left arm for covid-19 immunisation. The patient didn't receive BNT162b2 (BNT162B2). The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HAEMORRHAGIC STROKE (hospitalization, disability, medically significant) with onset 25Oct2022 at 15:45, outcome "not recovered", described as "right basal ganglia cerebrovascular-stroke"; SPEECH DISORDER (hospitalization, disability, medically significant), outcome "not recovered", described as "occupational, physical and speech"; PARALYSIS (hospitalization, disability, medically significant), outcome "not recovered", described as "No use to left arm, leg"; WRONG PRODUCT ADMINISTERED (non-serious), outcome "unknown", described as "Wrong vaccine administered". The patient was hospitalized for haemorrhagic stroke, speech disorder, paralysis (hospitalization duration: 22 day(s)). The events "right basal ganglia cerebrovascular-stroke", "occupational, physical and speech" and "no use to left arm, leg" required emergency room visit. Therapeutic measures were taken as a result of haemorrhagic stroke, speech disorder, paralysis.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5, BNT162b2 has been requested and will be submitted if and when received.
(L) Deltoid inflammation and redness (patient would not hold still when shot was administered).
Positive covid results.; Positive covid results.; booster dose; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 60 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 06Oct2021 13:00 (Lot number: EW0217) at the age of 59 years as dose 3 (booster), single, administered in arm left, administration date 09Feb2021 10:00 (Lot number: EL3247) as dose 2, single and administered in arm left, administration date 19Jan2021 10:00 (Lot number: EL3247) as dose 1, single for covid-19 immunisation. Relevant medical history included: "diabetes" (unspecified if ongoing); "high cholesterol" (unspecified if ongoing); "hypothyroid" (unspecified if ongoing); "Known allergies: red meat" (unspecified if ongoing), notes: Known allergies: red meat. Concomitant medication(s) included: FLU, administration date 06Oct2021. The following information was reported: IMMUNISATION (medically significant) with onset 06Oct2021 13:00, outcome "unknown", described as "booster dose"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 05Jan2022 09:00, outcome "recovering" and all described as "Positive covid results.". The event "positive covid results." and "positive covid results." was evaluated at the physician office visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (17Jun2021) negative, notes: Nasal Swab; (23Sep2021) negative, notes: Nasal Swab; (07Jan2022) positive. Therapeutic measures were not taken as a result of drug ineffective, covid-19. Additional information: The patient reported she was aware of symptoms on 05Jan2022.
On 7/3/01, area was red and swollen, post vax. Pt returned on 7/13/01 and presented with redness and "hardness" in area.
Severe pain in arm radiating into her neck and unable to move her arm, have started on MEDROL DOSEPAK today and outcome unknown at this time.
I developed pain and then numbness along distribution of my left lateral cutaneous femoral nerve ( pain and numbness ofver atneriolateral aspect of my left thigh ).  As of today 3/27/2012, numbness persists but pain seems to be decreasing.
generalized rash over trunk, face & extremities with classic pox like vessels with erythematous bases.
Above client received a Pfizer Booster. No s/s of adverse event. Client was noted to be in stable condition in the post-op vaccination area. No c/o pain and/or discomfort. No s/s of respiratory distress and/or shortness of breath. Client was d/c w/ family after 15 min in the post-vax area w/ family.
Client reports feeling "Warm and flushed". Denies Shortness of breath, tingling, itching, or pain at injection site. No warmth or erythema assessed at injection site.
Vaccine given 6/25/01, on 7/7, developed fine rash see over body with low grade temp
Yesterday the site of the injection started to itch, it is red and irritated and my shoulder hurt.
immediately after infection, pt reported dizziness, EMT and MD notified, pt then experienced syncope for approx 20 seconds, spontaneously resolved.  normal vital signs.  tolerated food/drink after, talkative and in good spirits shortly after regaining consciousness, no head trauma or fall.  pt arranged for someone to drive her home.  did not require hospital evaluation.
SHORT OF BREATH; FATIGUE; HEADACHE; GENERALISED ACHING; This spontaneous report received from a patient concerned a 33 year old female. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included the patient had no known drug allergies.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 202A21A, expiry: UNKNOWN) dose was not reported, administered on 11-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On APR-2021, treatment medications included: ibuprofen. On 11-APR-2021, the subject experienced generalised aching. On 24-APR-2021, the subject experienced short of breath. On 24-APR-2021, the subject experienced fatigue. On 24-APR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from generalised aching on 12-APR-2021, and had not recovered from fatigue, headache, and short of breath. This report was non-serious.
The vaccine clinic was run by facility at College. The staff did NOT give a Covid vaccine card. They provided the vaccine name and lot # on an unopened bandaid as "proof" of vaccination.
On April 6 a.m. developed fewer-like symptoms with muscle pain typical foe fewer with these symptoms steadily worsening by evening. Night shower at appr. 9 p.m. caused a feeling of spinal nerve pinch followed by acute pain during certain movements and breathing. Following day (Wednesday) spent in bed taking Ibuprophene thinking is just a nerve pinch. Called virtual appointment tele doctor who prescribed Katorolac which I took from Wednesday night to Thursday morning per prescription with no effects. On Thursday evening called tele doctor again and got Ibuprophene 800 mg prescription. It helped for 20-30 min only. Same evening coughed some blood. On Friday kept taking Ibuprophene for very temporary relieve. On Saturday April 10 was admitted to hospital and was hospitalized with blood cloth diagnosis for 4 days.
My COVID-19 infection symptoms started on 12/30/2022 in the morning at 8:00AM. I had a headache, sneezing, tiredness, cough and nausea. On Saturday I took a PCR test which was negative but on 01/01/2023 I took another home test which was positive. I called my doctor right away and she prescribed me with PAXLOVID for 5 days. I still have lingering cough but not like before. I am recovering slowly.
Information has been received from a registered nurse referring to an unspecified number of unspecified patients. On unknown dates, the patients were vaccinated with doses of improperly stored GARDASIL (Lot#: K010215, expiry date: 05-MAY-2017; K011562, expiry date: 08-APR-2017). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
This spontaneous report as received from a pharmacist via a physician refers to a 70 year old male patient. No medical history provided. In 2013, ("several weeks ago") the patient was vaccinated with ZOSTAVAX (subcutaneous, arm, indication: vaccination, dosing unknown). No concomitant medication provided. Following the vaccination the patient developed muscle aches in the injection site ar,. The outcome of persistent muscle aches in the injection site arm was reported as not recovered. The patient sought medical attention by contacting the physician. Additional information has been requested.
pt recvd vax; exp large inject site rxn; area was hot to touch; to md; tx w/ ice; md reportedly stated "pt has extended water to her elbow";
This case was reported by a nurse via call center representative and described the occurrence of adverse reaction in a adult patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced adverse reaction. On an unknown date, the outcome of the adverse reaction was unknown. It was unknown if the reporter considered the adverse reaction to be related to SHINGRIX. Additional details were provided as follows: The healthcare professional (HCP) reported adverse event during click to chat forum. The age at vaccination was not reported. The age group was not reported but was selected as adult as per vaccine indication. The HCP reported that the patient experienced a severe systemic reaction after receiving initial dose of SHINGRIX. No further details were available at the time of reporting.
Patient reported major swelling, redness and itching in area of vaccine. Also reported were muscle aches in pains in her entire body including her muscles in her legs.
Temperature 103 after shots.  Cries with movement/restless.  No redness/swelling at site.  (similar reaction after 4 month shots)
Experienced a weird reaction; A spontaneous report  was received from a consumer concerning an unknown-years-old Female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events experienced a weird reaction/vaccination site reaction.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On unknown date, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: unknown) via intramuscular route for prophylaxis of COVID-19 infection.  On unknown date, the patient experienced the event(s) experienced a weird reaction.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.  The outcome of the event experienced a weird reaction was unknown.
Pt was given vaccine, and told to wait 15 min. was left with sister (19) in the room. Approximately 5 min later I went to go check on patient and as I was walking to the room I can hear the sister yelling his name. I entered the room and patient was laying down on the bed. Sister had helped lay him down so he didn't fall. Patient woke up as soon as I entered room wondering what happened, we placed a cold pack under patient's neck and I fanned him until he gained color in his face. Then he was given cold water to sip on. Patient's vitals were taken and he was seen by provider before letting him leave with sister.
VACCINE ADMINISTERED TO PATIENT AFTER IT HAD BEEN IN ROOM TEMPERATURE FOR 7 HOURS; VACCINE LEFT OUT AT ROOM TEMPERATURE FOR 7 HOURS; This spontaneous report received from a pharmacist concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 09-JUN-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 09-JUN-2021, the subject experienced vaccine administered to subject after it had been in room temperature for 7 hours. On 09-JUN-2021, the subject experienced vaccine left out at room temperature for 7 hours. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the vaccine administered to patient after it had been in room temperature for 7 hours and vaccine left out at room temperature for 7 hours was not reported. This report was non-serious.
Information has been received from a physician concerning a 5 year old female who on 10-AUG-2009 was vaccinated with a dose of VARIVAX (Merck) (lot #, route and site of administration not reported).  Concomitant therapy included DTAP. On 13-AUG-2009 the patient experienced soreness around the injection site in addition to an abscess that was 3 inches in diameter and warm to the touch.  Unspecified medical attention was sought.  At the time of reporting the patient's outcome was unknown.  No further information is available.
This spontaneous report was received from a healthcare worker referring to a patient of unknown age and gender. The patient's pertinent medical history and drug reactions/allergies were not reported. On 02-FEB-2016, the patient was vaccinated with a dose of GARDASIL (lot # L020015 and expiration date August 2017, unknown route), which was exposed to temperatures outside of the recommended range. There were no concomitant medications provided. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Gradual increase in soreness at injection site and bruise at injection site.  Swelling in armpit area on same side as injection.  Feelings of foggyness and tiredness.  Puffiness of face in eye areas.  Sensitivity and bleeding of the gums when brushing teeth.  One week later symptoms have almost disappeared.
FELT FLUISH; FELT CRUMMY; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, the patient experienced felt fluish, and felt crummy. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from felt fluish, and felt crummy. This report was non-serious.
This case was reported by a pharmacist and described the occurrence of hepatitis B surface antigen positive in an adult male subject who was vaccinated with Engerix B (GlaxoSmithKline) for prophylaxis.  Concurrent medical conditions included hemodialysis.  On an unspecified date the subject received unspecified dose of Engerix B (unknown).  At an unspecified time after vaccination with Engerix B, the subject experienced hepatitis B surface antigen positive and lack of effect.  At the time of reporting the events were worse. Follow-up received on 18 September 2007 via the clinical pharmacist.  It was reported that the subject was a 68 year old male with a history of coronary artery disease and T-cell lymphoma stage IV.  He was vaccinated with Engerix-B on 05 July 2007.  On 06 July 2007, the hepatitis B surface antigen was negative.  A follow-up test on 09 July 2007 was negative.  Subsequent testing on 08 August 2007 was also negative.  The pharmacist considered that the events were resolved and possibly related to the use of Engerix-B.
Pneumonia; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PNEUMONIA (Pneumonia) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 045A21A and 022M20A) for COVID-19 vaccination.     The patient's past medical history included Leukemia (No special treatment for leukemia received.) and White blood cell count (10000 points). Concomitant products included PRAVASTATIN and GEMFIBROZIL for an unknown indication.   On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 21-Mar-2021, the patient experienced PNEUMONIA (Pneumonia) (seriousness criterion hospitalization). The patient was hospitalized on 21-Mar-2021 due to PNEUMONIA. At the time of the report, PNEUMONIA (Pneumonia) outcome was unknown. Not Provided          Patient was treated with Levaquin, IV hydration with magnesium.; Sender's Comments: Limited information regarding the event has been provided at this time and a causal relationship cannot be excluded
Vaccine was reconstituted with only 0.8 mL instead of 1.8 mL. No adverse event was reported.
pt recv vax 6JUN96 & 8JUN96 pt devel a fever of 101 & malaise;10JUN96 broke out w/chickenpox;pt also had a swollen throat w/vesicles down throat;pt seen by MD on 13JUN96;20JUN96 pt had completely recovered;
Tachycardia. Received vax on 27 Dec, no problems that day or on the 28th. On the 29th, HR was elevated compared to baseline upon awakening, got worse throughout day with interspersed palpitations and SVT -- did not respond to fluids or rest. Did not fell anxious, but HR kept climbing, reached 180s -- > went to ED at 10PM. Found to be hypokalemic with mildly elevated D-dimer -- > chest CT to r/o pulmonary embolism (none found).   HR responded to fluid boluses and K+ supplementation; was in 90s at time of discharge from ED (above baseline, but much improved). Completely normal today
Patient 10 hours after injection developed generalized itching with no rash..She then devoped waterry diarrhea that led to severe dehaydration leading to ICU admisiion for treatment and close observation.There was some suspicion of mild CHF but this subsequently was negative
Resident received the vaccine around 1:40PM on 6/23/2021. She waited in the office where vaccine was given with no adverse symptoms reported at end of 15 minute monitoring. She went to work as CNA for her shift and at 2:30PM began to complain of dizziness, double vision, anxiety, weakness and nausea without vomiting. Vital signs where taken. Vital signs at 2:30 were BP=138/48, P=86. T=98.1 and 02 sat=99%. Vitals at 2:45: BP=149/98, P=77, T=98.1, 02sat=99, Vitals at 3:00PM: BP=141/92, P=98, T=97.6, 02sat=94. Resident was encouraged to go the urgent care. Her mother picked her up around 3:15PM.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. On 01-OCT-2013 the patient was vaccinated with M-M-R II (reported batch # H018950 corresponding with lot # 1483AA; expiration date 18-OCT-2014). The vaccine was exposed to temperature exposures for 50F for 85 minutes, 47F for 15 minutes, 48F for 35 minutes, 52 F for 95 minutes, 48F for 30 minutes on 20-SEP-2013 and 48F for 45 minutes on 25-SEP-2013. No known adverse effects. This case is linked to case 1310USA001610, 1310USA008360, 1310USA008361, 1310USA008362, 1310USA008363, 1310USA008364, 1310USA008365, 1310USA008366, 1310USA008367, 1310USA008368, 1310USA008369, 1310USA008370, 1310USA008371, 1310USA008372, 1310USA008373, 1310USA008374, 1310USA008375, 1310USA008376, 1310USA008377, 1310USA008378, 1310USA008379, 1310USA008380, 1310USA008381, 1310USA008382, 1310USA008383, 1310USA008384, 1310USA008385, 1310USA008386, 1310USA008387, 1310USA008388, 1310USA008389, 1310USA008390, 1310USA008391, 1310USA008392, 1310USA008393, 1310USA008394, 1310USA008395, 1310USA008396, 1310USA008397, 1310USA008398, 1310USA008399, 1310USA008400, 1310USA008401, 1310USA008402, 1310USA008403, 1310USA008405, 1310USA008406 and 1310USA008407 (same reporter link). Additional information has been requested.
233 Patients given expired doses; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (233 Patients given expired doses) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Dec-2021 at 2:18 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (233 Patients given expired doses). On 03-Dec-2021, EXPIRED PRODUCT ADMINISTERED (233 Patients given expired doses) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant medication information was reported.  8 vials removed from -20C freezer at 12:30pm, 3 Dec 2021,thawed for 30 min at room temp, drawn up and placed in fridge (3.8C) for duration of clinic, from 1pm-4pm on 3 Dec 2021.  No Treatment medications were provided.
chill and stuff; diarrhea; nausea; This is a spontaneous report from a contactable consumer (Patient wife).  A male patient of an unspecified age received first dose of bnt162b2(PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number was not reported), via an unspecified route of administration on 05Feb2021 as dose1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. Patient's wife reported that she and her husband received the first vaccine on 05Feb2021. On 10Feb2021 she got COVID-19 and her husband was negative. She stated her husband had experienced "chills and stuff, no fever, no body aches, but he had nausea and diarrhea. She asked if she should have him retested. The patient underwent lab tests and procedures which included Covid test negative. Outcome of the events was unknown.    Information on lot/ batch number has been requested.  Follow-up attempts are completed. No further information is expected.
The purpose of this note is to report the rash side affect I had after the first dose of the Moderna Covid-19 vaccine that I received in the clinic. I received the vaccine 4/1/2021 about 8 PM. Today's date is 4/5/2021. I can send a picture if that would be helpful. One thing to be aware of is that I almost always get a body rash and minor body aches when I start to get sick or when I get very run down. Rest has always taken care of it. This red rash is brighter red than I have had before and it feels like a mild to medium sunburn, which has not occurred in the past. The rash started one day after receiving the vaccine. The second day it covered most of my body and got much brighter red and, as mentioned, felt like a sunburn. The third day was about the same, but later in the day (today)it appears to be slowly fading.